Bell Potter says this ASX 200 stock can rise 38% and pay a 6% dividend yield

Major upside and a generous dividend yield could be on offer with this name.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

If you are searching for a combination of major upside and an above-average dividend yield, then look no further than the ASX 200 stock in this article.

That's because the team at Bell Potter believes its shares can deliver both over the next 12 months.

A woman presenting company news to investors looks back at the camera and smiles.

Image source: Getty Images

Which ASX 200 stock?

The stock that Bell Potter is bullish on right now is Harvey Norman Holdings Ltd (ASX: HVN).

It is of course one of Australia's largest retailers with a growing network of stores selling electronic and household goods across the globe.

Bell Potter has been looking at its recent half-year result and while it was a touch softer than expected, it remains positive. It said:

Harvey Norman (HVN)'s 1H26 result back in February saw some minor misses, however with aggregate system sales +7% and the least variance in the Australian Franchising division supported by strong franchising operations margins.

The Australian business saw comparable sales growth easing towards the ~1% level (as per BPe) in the last 6 weeks of 1H (21-Nov to 31-Dec) as HVN cycled ~9% comps. The month of Jan in 2H26 started at a slightly better 3.6% comparable sales growth in Australia (cycling +2.1%), however tougher comps 2H to be cycled in Feb-Jun. The Home, Lifestyle and Technology categories have remained robust during 1H26.

Major upside and a big dividend yield

According to the note, the broker has retained its buy rating with a reduced price target of $6.70 (from $8.30).

Based on its current share price of $4.87, this implies potential upside of 38% for investors over the next 12 months.

In addition, it is expecting the ASX 200 stock to provide investors with a generous 6.1% fully franked dividend yield over the period. This boosts the total potential return to over 44%.

Bell Potter thinks its shares are being undervalued by the market at just 13x forward earnings. Commenting on its buy recommendation, Bell Potter said:

While our preference skews to category specialists with balance sheet strength, we see HVN's well balanced geographical diversification somewhat offsetting the multi-category risks. Following the sharp sell-off in the name since Oct-25, HVN's 1-year forward P/E of ~13x (as per BPe) appears attractive considering the new store driven growth in international retailing (UK, Malaysia, Croatia), refit program in Australia and opportunities to grow their real estate portfolio as Australia's single largest owner in large format retail with a global portfolio of ~$4.6b.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has positions in and has recommended Harvey Norman. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Broker Notes

Man drawing an upward line on a bar graph symbolising a rising share price.
Broker Notes

Broker says this ASX 200 stock could rocket 50%+ in 12 months

Bell Potter has good things to say about this stock.

Read more »

Broker Notes

2 ASX 200 stocks drawing fresh buy ratings this week 

These shares have solid upside.

Read more »

Time to sell written on a clock.
Broker Notes

Sell alert! Why this expert is calling time on Magellan and Ramsay Health Care shares

A leading expert forecasts growing headwinds for Magellan and Ramsay Health Care shares. But why?

Read more »

Pilot on the phone looking distraught.
Broker Notes

Sell alert! Why this expert is ditching Qantas shares for this ASX 200 defence stock

A leading expert is selling Qantas shares and buying this surging ASX 200 defence stock instead. But why?

Read more »

Medical workers examine an x-ray or scan in a hospital laboratory.
Broker Notes

Up 64%, 3 reasons this expert predicts Pro Medicus shares will keep on giving

A leading expert forecasts more outperformance from the surging Pro Medicus share price.

Read more »

Business man marking buy on board and underlining it.
Broker Notes

Leading brokers name 3 ASX shares to buy today

Brokers believe that now could be the time to buy these shares.

Read more »

A scientist in a white coat and glasses puts her arms in the air in a sign of strength and success.
Broker Notes

Morgans tips a 600%+ return for this ASX biotech stock

Good clinical study progress has the broker bullish on this company.

Read more »

Wlorker on a laptop on top of solar panels.
Broker Notes

Up 8%, should I buy the rebound in Origin Energy shares today?

A leading analyst provides his forecast for Origin Energy’s rebounding shares.

Read more »